Free Trial

Mirum Pharmaceuticals (MIRM) Competitors

Mirum Pharmaceuticals logo
$71.52 +2.46 (+3.56%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$71.87 +0.35 (+0.49%)
As of 08/22/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRM vs. VTRS, ASND, RDY, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, and ROIV

Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

Mirum Pharmaceuticals vs. Its Competitors

Mirum Pharmaceuticals (NASDAQ:MIRM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

79.9% of Viatris shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Viatris. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Viatris' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mirum Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viatris
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mirum Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Viatris. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum Pharmaceuticals$429.16M8.37-$87.94M-$1.21-59.11
Viatris$14.12B0.88-$634.20M-$2.90-3.67

Mirum Pharmaceuticals presently has a consensus price target of $74.13, indicating a potential upside of 3.64%. Viatris has a consensus price target of $10.40, indicating a potential downside of 2.35%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Viatris
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Mirum Pharmaceuticals has a net margin of -13.65% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals-13.65% -24.76% -8.50%
Viatris -24.57%16.54%7.06%

Summary

Mirum Pharmaceuticals beats Viatris on 12 of the 17 factors compared between the two stocks.

Get Mirum Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MIRM vs. The Competition

MetricMirum PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.47B$3.11B$5.76B$9.58B
Dividend YieldN/A2.23%4.41%4.10%
P/E Ratio-59.1120.8831.1026.04
Price / Sales8.37349.56435.26103.29
Price / CashN/A43.1937.7358.48
Price / Book14.088.129.536.61
Net Income-$87.94M-$54.72M$3.26B$265.56M
7 Day Performance5.28%2.63%2.10%1.95%
1 Month Performance34.82%2.78%2.82%-0.37%
1 Year Performance73.93%11.01%30.56%19.02%

Mirum Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MIRM
Mirum Pharmaceuticals
3.5068 of 5 stars
$71.52
+3.6%
$74.13
+3.6%
+74.5%$3.47B$429.16M-59.11140News Coverage
Positive News
VTRS
Viatris
1.6454 of 5 stars
$10.63
+0.2%
$10.40
-2.2%
-9.0%$12.37B$14.74B-3.6732,000Analyst Upgrade
ASND
Ascendis Pharma A/S
3.452 of 5 stars
$194.08
-2.1%
$242.93
+25.2%
+39.4%$12.13B$490.75M-37.611,017News Coverage
Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
3.1111 of 5 stars
$14.26
+0.2%
$16.95
+18.9%
-12.1%$11.87B$3.81B21.6027,811News Coverage
Positive News
QGEN
QIAGEN
3.827 of 5 stars
$48.66
-1.4%
$49.69
+2.1%
+9.4%$10.97B$1.98B28.755,765Positive News
MRNA
Moderna
4.4344 of 5 stars
$28.09
+0.2%
$43.59
+55.2%
-66.5%$10.90B$3.24B-3.735,800Analyst Forecast
BBIO
BridgeBio Pharma
4.6808 of 5 stars
$49.02
-4.5%
$61.35
+25.2%
+97.2%$9.81B$221.90M-11.99400Insider Trade
VRNA
Verona Pharma PLC American Depositary Share
2.4117 of 5 stars
$105.79
+0.5%
$109.00
+3.0%
+290.2%$8.96B$42.28M-106.8630Short Interest ↓
ELAN
Elanco Animal Health
3.0971 of 5 stars
$17.72
-1.4%
$17.33
-2.2%
+22.4%$8.92B$4.44B20.609,000Analyst Downgrade
BPMC
Blueprint Medicines
0.4892 of 5 stars
$129.46
flat
$130.00
+0.4%
N/A$8.36B$562.12M-52.41640
ROIV
Roivant Sciences
3.4485 of 5 stars
$11.81
-0.3%
$16.50
+39.7%
+2.1%$8.06B$29.05M-16.87860Insider Trade

Related Companies and Tools


This page (NASDAQ:MIRM) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners